Monza, Italy

Filippo Magaraci

USPTO Granted Patents = 3 

 

Average Co-Inventor Count = 5.1

ph-index = 1


Company Filing History:


Years Active: 2023-2025

Loading Chart...
Loading Chart...
3 patents (USPTO):Explore Patents

Title: Filippo Magaraci: Innovator in Pharmaceutical Chemistry

Introduction

Filippo Magaraci is a notable inventor based in Monza, Italy. He has made significant contributions to the field of pharmaceutical chemistry, particularly in the development of innovative processes and compounds.

Latest Patents

Magaraci holds two patents that showcase his expertise. The first patent details a process for the preparation of (R)-4-(1-(6-(4-(trifluoromethyl)benzyl)-6-azaspiro[2.5]octane-5-carboxamido)-cyclopropyl) benzoic acid or a salt thereof. This invention outlines a multi-step process involving the conversion of specific compounds using a Wittig reagent and the Makosza reaction, ultimately leading to the desired cyclopropane compound. The second patent focuses on a pharmaceutical combination of an EP4 antagonist and immune checkpoint inhibitors for the treatment of tumors. This combination includes the sodium salt of the previously mentioned compound and is characterized by a specific powder XRD spectrum.

Career Highlights

Magaraci is currently associated with Rottapharm Biotech S.r.l., where he continues to innovate in the pharmaceutical sector. His work has been instrumental in advancing therapeutic options for various medical conditions.

Collaborations

He collaborates with esteemed colleagues such as Lucio C Rovati and Antonio Giordani, contributing to a dynamic research environment that fosters innovation.

Conclusion

Filippo Magaraci's contributions to pharmaceutical chemistry through his patents and collaborations highlight his role as a key innovator in the field. His work continues to impact the development of new therapeutic solutions.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…